Niall Martin

Outlook Microsoft Office 365 Amazon AWS Google Tag Manager Mobile Friendly Hotjar Vimeo reCAPTCHA Google Maps Gravity Forms Nginx WordPress.org Remote Circle

dna damage response & oncology biotechnology research dna damage response ddr pathways cancer treatments atr inhibitor pol theta inhibitor drug discovery platform synthetic lethality parp inhibitors cancer therapy immuno-oncology combinations novel cancer therapies clinical trials oncology tumor cells chemotherapy resistance radioligand therapies nucleases development replication stress solid tumors targeted therapies oral anticancer agents drug screening patient selection dcoder platform first-in-class therapies biotherapeutics biotech innovation molecular targets tumor sensitivity cancer cell repair cancer genetics tumor microenvironment biomarker discovery mechanism of action dual therapy personalized medicine therapeutic index high unmet need cancers tumorigenesis telomere maintenance dna repair mechanisms cancer resistance oncology drug development clinical efficacy safety & tolerability cancer patient outcomes preventative treatments biotechnology cancer therapies ddr precision medicine art0380 polθ inhibitor art6043 drug discovery therapeutic impact cancer treatment innovative therapies patient outcomes research collaborations healthcare providers pharmaceutical industry cancer research therapeutic candidates proprietary platform dcoder funding sustainable practices diverse workplace patient-centric hard-to-treat cancers strategic partnerships global approach transformative results health care health wellness & fitness hospital & health care